The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy

Background. As a parameter integrating platelet (P), neutrophil (N), and lymphocyte (L) levels, the systemic immune-inflammation index (SII) has been used as a prognostic marker for patient survival in various types of solid malignant tumors. However, there is no in-depth study in non-small-cell lun...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yanan Zhang, Zeyang Chen, Feng Jin, Dong Guo, Qingqing Chen, Zhengcao Liu, Shengjun Ji, Guanqi Gao
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Pathology RB1-214
Acceso en línea:	https://doaj.org/article/00e4cc3c5a1740f48490f361d8165774
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:00e4cc3c5a1740f48490f361d8165774
record_format	dspace
spelling	oai:doaj.org-article:00e4cc3c5a1740f48490f361d81657742021-11-08T02:36:22ZThe Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy1466-186110.1155/2021/2910892https://doaj.org/article/00e4cc3c5a1740f48490f361d81657742021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/2910892https://doaj.org/toc/1466-1861Background. As a parameter integrating platelet (P), neutrophil (N), and lymphocyte (L) levels, the systemic immune-inflammation index (SII) has been used as a prognostic marker for patient survival in various types of solid malignant tumors. However, there is no in-depth study in non-small-cell lung cancer (NSCLC) patients with brain metastases after stereotactic radiotherapy. Therefore, we performed a retrospective analysis to determine the clinical and prognostic value of the SII in NSCLC patients with brain metastases who underwent stereotactic radiotherapy. Materials and Methods. We enrolled 124 NSCLC patients with brain metastases treated with stereotactic radiotherapy in our hospital between May 2015 and June 2018. We obtained all baseline blood samples within one week prior to stereotactic radiotherapy. The SII was calculated by the following formula: neutrophil counts×platelet counts/lymphocyte counts. The optimal cutoff value of the SII for predicting prognosis was assessed by receiver operating characteristic (ROC) curves with the maximum log-rank values. The discriminative ability of predicting prognosis was calculated and compared using the Kaplan–Meier method and log-rank test. The hazard ratio (HR) and 95% confidence interval (CI) were combined to evaluate the prognostic impact of the blood index on overall survival (OS) and progression-free survival (PFS). Only those parameters that proved to be associated with statistically significant differences in clinical outcomes were compared in multivariate analysis using a multiple Cox proportional hazard regression model to identify independent prognostic factors. Results. Of the total enrolled patients, 53.2% and 46.8% have high SII and low SII, respectively. In this study, Kaplan–Meier curve analysis revealed that the median PFS was 9 months (range: 2–22 months) and the median OS was 18 months (range: 4–37 months). Applying an optimal cutoff of 480 (SII), the median PFS was better in the low SII group patients (11.5 vs. 9 months), and the median OS was significantly longer in the low SII group patients (20 vs. 18 months). A SII>480 was significantly associated with worse OS (HR: 2.196; 95% CI 1.259–3.832; P=0.006) and PFS (HR: 2.471; 95% CI 1.488–4.104; P<0.001) according to univariate analysis. In multivariate analysis, only age (HR: 2.159; 95% CI 1.205–3.869; P=0.010), KPS (HR: 1.887; 95% CI 1.114–3.198; P=0.018), and SII (HR: 1.938; 95% CI 1.046–3.589; P=0.035) were independently correlated with OS, and SII (HR: 2.224; 95% CI 1.298–3.810; P=0.004) was an independent prognostic predictor of PFS, whereas we found that other inflammation-based indices lost their independent value. Conclusions. The SII, which is an integrated blood parameter based on platelet, neutrophil, and lymphocyte counts, may be an independent prognostic indicator and may be useful for the identification of NSCLC patients with brain metastases after stereotactic radiotherapy at high risk for recurrence.Yanan ZhangZeyang ChenFeng JinDong GuoQingqing ChenZhengcao LiuShengjun JiGuanqi GaoHindawi LimitedarticlePathologyRB1-214ENMediators of Inflammation, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Pathology RB1-214
spellingShingle	Pathology RB1-214 Yanan Zhang Zeyang Chen Feng Jin Dong Guo Qingqing Chen Zhengcao Liu Shengjun Ji Guanqi Gao The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy
description	Background. As a parameter integrating platelet (P), neutrophil (N), and lymphocyte (L) levels, the systemic immune-inflammation index (SII) has been used as a prognostic marker for patient survival in various types of solid malignant tumors. However, there is no in-depth study in non-small-cell lung cancer (NSCLC) patients with brain metastases after stereotactic radiotherapy. Therefore, we performed a retrospective analysis to determine the clinical and prognostic value of the SII in NSCLC patients with brain metastases who underwent stereotactic radiotherapy. Materials and Methods. We enrolled 124 NSCLC patients with brain metastases treated with stereotactic radiotherapy in our hospital between May 2015 and June 2018. We obtained all baseline blood samples within one week prior to stereotactic radiotherapy. The SII was calculated by the following formula: neutrophil counts×platelet counts/lymphocyte counts. The optimal cutoff value of the SII for predicting prognosis was assessed by receiver operating characteristic (ROC) curves with the maximum log-rank values. The discriminative ability of predicting prognosis was calculated and compared using the Kaplan–Meier method and log-rank test. The hazard ratio (HR) and 95% confidence interval (CI) were combined to evaluate the prognostic impact of the blood index on overall survival (OS) and progression-free survival (PFS). Only those parameters that proved to be associated with statistically significant differences in clinical outcomes were compared in multivariate analysis using a multiple Cox proportional hazard regression model to identify independent prognostic factors. Results. Of the total enrolled patients, 53.2% and 46.8% have high SII and low SII, respectively. In this study, Kaplan–Meier curve analysis revealed that the median PFS was 9 months (range: 2–22 months) and the median OS was 18 months (range: 4–37 months). Applying an optimal cutoff of 480 (SII), the median PFS was better in the low SII group patients (11.5 vs. 9 months), and the median OS was significantly longer in the low SII group patients (20 vs. 18 months). A SII>480 was significantly associated with worse OS (HR: 2.196; 95% CI 1.259–3.832; P=0.006) and PFS (HR: 2.471; 95% CI 1.488–4.104; P<0.001) according to univariate analysis. In multivariate analysis, only age (HR: 2.159; 95% CI 1.205–3.869; P=0.010), KPS (HR: 1.887; 95% CI 1.114–3.198; P=0.018), and SII (HR: 1.938; 95% CI 1.046–3.589; P=0.035) were independently correlated with OS, and SII (HR: 2.224; 95% CI 1.298–3.810; P=0.004) was an independent prognostic predictor of PFS, whereas we found that other inflammation-based indices lost their independent value. Conclusions. The SII, which is an integrated blood parameter based on platelet, neutrophil, and lymphocyte counts, may be an independent prognostic indicator and may be useful for the identification of NSCLC patients with brain metastases after stereotactic radiotherapy at high risk for recurrence.
format	article
author	Yanan Zhang Zeyang Chen Feng Jin Dong Guo Qingqing Chen Zhengcao Liu Shengjun Ji Guanqi Gao
author_facet	Yanan Zhang Zeyang Chen Feng Jin Dong Guo Qingqing Chen Zhengcao Liu Shengjun Ji Guanqi Gao
author_sort	Yanan Zhang
title	The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy
title_short	The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy
title_full	The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy
title_fullStr	The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy
title_full_unstemmed	The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy
title_sort	value of the systemic immune-inflammation index in predicting survival outcomes in patients with brain metastases of non-small-cell lung cancer treated with stereotactic radiotherapy
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/00e4cc3c5a1740f48490f361d8165774
work_keys_str_mv	AT yananzhang thevalueofthesystemicimmuneinflammationindexinpredictingsurvivaloutcomesinpatientswithbrainmetastasesofnonsmallcelllungcancertreatedwithstereotacticradiotherapy AT zeyangchen thevalueofthesystemicimmuneinflammationindexinpredictingsurvivaloutcomesinpatientswithbrainmetastasesofnonsmallcelllungcancertreatedwithstereotacticradiotherapy AT fengjin thevalueofthesystemicimmuneinflammationindexinpredictingsurvivaloutcomesinpatientswithbrainmetastasesofnonsmallcelllungcancertreatedwithstereotacticradiotherapy AT dongguo thevalueofthesystemicimmuneinflammationindexinpredictingsurvivaloutcomesinpatientswithbrainmetastasesofnonsmallcelllungcancertreatedwithstereotacticradiotherapy AT qingqingchen thevalueofthesystemicimmuneinflammationindexinpredictingsurvivaloutcomesinpatientswithbrainmetastasesofnonsmallcelllungcancertreatedwithstereotacticradiotherapy AT zhengcaoliu thevalueofthesystemicimmuneinflammationindexinpredictingsurvivaloutcomesinpatientswithbrainmetastasesofnonsmallcelllungcancertreatedwithstereotacticradiotherapy AT shengjunji thevalueofthesystemicimmuneinflammationindexinpredictingsurvivaloutcomesinpatientswithbrainmetastasesofnonsmallcelllungcancertreatedwithstereotacticradiotherapy AT guanqigao thevalueofthesystemicimmuneinflammationindexinpredictingsurvivaloutcomesinpatientswithbrainmetastasesofnonsmallcelllungcancertreatedwithstereotacticradiotherapy AT yananzhang valueofthesystemicimmuneinflammationindexinpredictingsurvivaloutcomesinpatientswithbrainmetastasesofnonsmallcelllungcancertreatedwithstereotacticradiotherapy AT zeyangchen valueofthesystemicimmuneinflammationindexinpredictingsurvivaloutcomesinpatientswithbrainmetastasesofnonsmallcelllungcancertreatedwithstereotacticradiotherapy AT fengjin valueofthesystemicimmuneinflammationindexinpredictingsurvivaloutcomesinpatientswithbrainmetastasesofnonsmallcelllungcancertreatedwithstereotacticradiotherapy AT dongguo valueofthesystemicimmuneinflammationindexinpredictingsurvivaloutcomesinpatientswithbrainmetastasesofnonsmallcelllungcancertreatedwithstereotacticradiotherapy AT qingqingchen valueofthesystemicimmuneinflammationindexinpredictingsurvivaloutcomesinpatientswithbrainmetastasesofnonsmallcelllungcancertreatedwithstereotacticradiotherapy AT zhengcaoliu valueofthesystemicimmuneinflammationindexinpredictingsurvivaloutcomesinpatientswithbrainmetastasesofnonsmallcelllungcancertreatedwithstereotacticradiotherapy AT shengjunji valueofthesystemicimmuneinflammationindexinpredictingsurvivaloutcomesinpatientswithbrainmetastasesofnonsmallcelllungcancertreatedwithstereotacticradiotherapy AT guanqigao valueofthesystemicimmuneinflammationindexinpredictingsurvivaloutcomesinpatientswithbrainmetastasesofnonsmallcelllungcancertreatedwithstereotacticradiotherapy
_version_	1718443062175203328

The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy

Ejemplares similares